Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2019-12-10 , DOI: 10.1111/jdi.13179
Hajime Yamakage ₁ , Masashi Tanaka _{1,

2} , Takayuki Inoue ₁ , Shinji Odori ₁ , Toru Kusakabe ₁ , Noriko Satoh-Asahara ₁

Affiliation

Our aims were to examine the add‐on effects of a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal muscle mass (SMM) negative regulator, myostatin; and a metabolic regulator, irisin, in patients with type 2 diabetes.

中文翻译：

达格列净对日本 2 型糖尿病患者血清成纤维细胞生长因子 21 和肌因子水平以及肌肉质量的影响：一项随机对照试验。

我们的目的是检查钠-葡萄糖协同转运蛋白 2 抑制剂达格列净与现有抗糖尿病治疗相比对人体测量/代谢参数、内分泌调节剂成纤维细胞生长因子 21 (FGF21) 水平的附加影响；骨骼肌质量 (SMM) 负调节因子，肌肉生长抑制素；以及 2 型糖尿病患者的代谢调节剂鸢尾素。

更新日期：2019-12-10

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11